Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison

All tirzepatide doses showed statistically significantly greater reductions in glycated haemoglobin, body weight, and body mass index from baseline to week 40.

• Tirzepatide 5, 10, and 15 mg resulted in larger reductions in glycated haemoglobin compared to semaglutide 0.5 mg.
• Patients using tirzepatide had greater odds of achieving HbA1c targets of ≤ 6.5 % and < 7.0 % than those on semaglutide.
• Weight loss targets of ≥ 5 % and ≥ 10 % were more frequently met by patients taking tirzepatide compared to those on semaglutide.
• The adverse event profile for all tirzepatide doses was comparable to that of semaglutide 0.5 mg, with no significant differences in gastrointestinal adverse events.

AI simplified